[Federal Register Volume 82, Number 55 (Thursday, March 23, 2017)]
[Proposed Rules]
[Pages 14835-14837]
[FR Doc No: 2017-05519]

-----------------------------------------------------------------------

DEPARTMENT OF TRANSPORTATION

Federal Aviation Administration

14 CFR Part 39

[Docket No. FAA-2017-0131; Directorate Identifier 2016-NM-186-AD]
RIN 2120-AA64

Airworthiness Directives; The Boeing Company Airplanes

AGENCY: Federal Aviation Administration (FAA), DOT.

ACTION: Notice of proposed rulemaking (NPRM).

-----------------------------------------------------------------------

SUMMARY: We propose to adopt a new airworthiness directive (AD) for
certain The Boeing Company Model 737-300, -400, and -500 series
airplanes. This proposed AD was prompted by a report of fatigue
cracking found in a certain fuselage frame common to the water tank
support intercostal clip located between certain stringers. This
proposed AD would require inspections for any cracking of a certain
fuselage frame, and repair if necessary. We are proposing this AD to
address the unsafe condition on these products.

DATES: We must receive comments on this proposed AD by May 8, 2017.

ADDRESSES: You may send comments, using the procedures found in 14 CFR
11.43 and 11.45, by any of the following methods:
     Federal eRulemaking Portal: Go to http://www.regulations.gov. Follow the instructions for submitting comments.
     Fax:<PHONE_NUMBER>.
     Mail: U.S. Department of Transportation, Docket
Operations, M-30, West Building Ground Floor, Room W12-140, 1200 New
Jersey Avenue SE., Washington, DC 20590.
     Hand Delivery: Deliver to Mail address above between 9
a.m. and 5 p.m., Monday through Friday, except Federal holidays.
    For service information identified in this NPRM, contact Boeing
Commercial Airplanes, Attention: Contractual & Data Services (C&DS),
2600 Westminster Blvd., MC 110-SK57, Seal Beach, CA 90740-5600;
telephone<PHONE_NUMBER>; Internet https://www.myboeingfleet.com. You may
view this referenced service information at the FAA, Transport Airplane
Directorate, 1601 Lind Avenue SW., Renton, WA. For information on the
availability of this material at the FAA, call<PHONE_NUMBER>. It is also
available on the Internet at http://www.regulations.gov by searching
for and locating Docket No. FAA-2017-0131.

Examining the AD Docket

    You may examine the AD docket on the Internet at http://www.regulations.gov by searching for and locating Docket No. FAA-2017-
0131; or in person at the Docket Management Facility between 9 a.m. and
5 p.m., Monday through Friday, except Federal holidays. The AD docket
contains this proposed AD, the regulatory evaluation, any comments
received, and other information. The street address for the Docket
Office (phone:<PHONE_NUMBER>) is in the ADDRESSES section. Comments will
be available in the AD docket shortly after receipt.

FOR FURTHER INFORMATION CONTACT: Galib Abumeri, Aerospace Engineer,
Airframe Branch, ANM-120L, FAA, Los Angeles Aircraft Certification
Office (ACO), 3960 Paramount Boulevard, Lakewood, CA 90712-4137; phone:
562-627-5324; fax:<PHONE_NUMBER>; email<EMAIL_ADDRESS>
SUPPLEMENTARY INFORMATION:

Comments Invited

    We invite you to send any written relevant data, views, or
arguments about this proposal. Send your comments to an address listed
under the ADDRESSES section. Include ``Docket No. FAA-2017-0131;
Directorate Identifier 2016-NM-186-AD'' at the beginning of your
comments. We specifically invite comments on the overall regulatory,
economic, environmental, and energy aspects of this proposed AD. We
will consider all comments received by the closing date and may amend
this proposed AD because of those comments.
    We will post all comments we receive, without change, to http://www.regulations.gov, including any personal information you provide. We
will also post a report summarizing each substantive verbal contact we
receive about this proposed AD.

Discussion

    We have received a report of fatigue cracking found in a certain
fuselage frame, Station (STA) 947.5 on the right side, common to the
water tank support intercostal clip located between certain stringers,
S-24R and S-25R. Ten cracks were reported on airplanes having line

numbers 2566 through 3132. Those airplanes had accumulated between
39,400 and 51,745 total flight cycles. The reported cracks were between
0.184 and 1.125 inch long. These cracks were found to be caused by
fatigue caused by cyclic loading of the fuselage, and out-of-plane
bending of the frame caused by the water tank loads. Fatigue cracking,
if not corrected, could grow in size and result in a severed frame.
Multiple adjacent severed frames would result in reduced structural
integrity of the airplane.

Related Service Information Under 1 CFR Part 51

    We reviewed Boeing Alert Service Bulletin 737-53A1357, dated August
9, 2016. The service information describes procedures for inspections
for any cracking of a certain fuselage frame, and repair if necessary.
This service information is reasonably available because the interested
parties have access to it through their normal course of business or by
the means identified in the ADDRESSES section.

FAA's Determination

    We are proposing this AD because we evaluated all the relevant
information and determined the unsafe condition described previously is
likely to exist or develop in other products of the same type design.

Proposed AD Requirements

    This proposed AD would require accomplishing the actions specified
in the service information described previously. For information on the
procedures and compliance times, see this service information at http://www.regulations.gov by searching for and locating Docket No. FAA-2017-
0131.

Costs of Compliance

    We estimate that this proposed AD affects 140 airplanes of U.S.
registry. We estimate the following costs to comply with this proposed
AD:

                                                 Estimated Costs
----------------------------------------------------------------------------------------------------------------
                                                                                Cost on U.S.
             Action                     Labor cost          Parts cost     Cost per product        operators
----------------------------------------------------------------------------------------------------------------
Inspection.....................  2 work-hours x $85 per               $0  $170 per            $23,800 per
                                  hour = $170 per                          inspection cycle.   inspection cycle.
                                  inspection cycle.
----------------------------------------------------------------------------------------------------------------

    We estimate the following costs to do any necessary repairs that
would be required based on the results of the proposed inspection. We
have no way of determining the number of aircraft that might need this
repair:

                                               On-condition Costs
----------------------------------------------------------------------------------------------------------------
                                                                                Cost per
                   Action                                 Labor cost                Parts cost        product
----------------------------------------------------------------------------------------------------------------
Repair.....................................  18 work-hour x $85 per hour =                  $100          $1,630
                                              $1,530.
----------------------------------------------------------------------------------------------------------------

Authority for This Rulemaking

    Title 49 of the United States Code specifies the FAA's authority to
issue rules on aviation safety. Subtitle I, section 106, describes the
authority of the FAA Administrator. Subtitle VII: Aviation Programs,
describes in more detail the scope of the Agency's authority.
    We are issuing this rulemaking under the authority described in
Subtitle VII, Part A, Subpart III, Section 44701: ``General
requirements.'' Under that section, Congress charges the FAA with
promoting safe flight of civil aircraft in air commerce by prescribing
regulations for practices, methods, and procedures the Administrator
finds necessary for safety in air commerce. This regulation is within
the scope of that authority because it addresses an unsafe condition
that is likely to exist or develop on products identified in this
rulemaking action.

Regulatory Findings

    We determined that this proposed AD would not have federalism
implications under Executive Order 13132. This proposed AD would not
have a substantial direct effect on the States, on the relationship
between the national Government and the States, or on the distribution
of power and responsibilities among the various levels of government.
    For the reasons discussed above, I certify this proposed
regulation:
    (1) Is not a ``significant regulatory action'' under Executive
Order 12866,
    (2) Is not a ``significant rule'' under the DOT Regulatory Policies
and Procedures (44 FR 11034, February 26, 1979),
    (3) Will not affect intrastate aviation in Alaska, and
    (4) Will not have a significant economic impact, positive or
negative, on a substantial number of small entities under the criteria
of the Regulatory Flexibility Act.

List of Subjects in 14 CFR Part 39

    Air transportation, Aircraft, Aviation safety, Incorporation by
reference, Safety.

The Proposed Amendment

    Accordingly, under the authority delegated to me by the
Administrator, the FAA proposes to amend 14 CFR part 39 as follows:

PART 39--AIRWORTHINESS DIRECTIVES

0
1. The authority citation for part 39 continues to read as follows:

    Authority:  49 U.S.C. 106(g), 40113, 44701.

Sec.  39.13   [Amended]

0
2. The FAA amends Sec.  39.13 by adding the following new airworthiness
directive (AD):

The Boeing Company: Docket No. FAA-2017-0131; Directorate Identifier
2016-NM-186-AD.

(a) Comments Due Date

    We must receive comments by May 8, 2017.

(b) Affected ADs

    None.

(c) Applicability

    This AD applies to The Boeing Company Model 737-300, -400, and -
500 series airplanes, certificated in any category, as identified in
Boeing Alert Service Bulletin 737-53A1357, dated August 9, 2016.

(d) Subject

    Air Transport Association (ATA) of America Code 53; Fuselage.

(e) Unsafe Condition

    This AD was prompted by a report of fatigue cracking found in a
certain fuselage frame common to the water tank support intercostal
clip located between certain stringers. We are issuing this AD to
detect and correct cracking, which could grow in size and result in
a severed frame. Multiple adjacent severed frames would result in
reduced structural integrity of the airplane.

(f) Compliance

    Comply with this AD within the compliance times specified,
unless already done.

(g) Inspection

    Before the accumulation of 34,000 total flight cycles or within
6,000 flight cycles after the effective date of this AD, whichever
occurs later, do a high frequency eddy current (HFEC) inspection for
any cracking in the fuselage frame at station (STA) 947.5 common to
the water tank support intercostal clip located between stringer S-
24R and S-25R, in accordance with the Accomplishment Instructions of
Boeing Alert Service Bulletin 737-53A1357, dated August 9, 2016.
    (1) If no cracking is found, repeat the inspection thereafter at
intervals not to exceed 12,000 flight cycles.
    (2) If any cracking is found: Before further flight, repair in
accordance with the Accomplishment Instructions of Boeing Alert
Service Bulletin 737-53A1357, dated August 9, 2016.

(h) Terminating Action

    Accomplishing the repair in accordance with the Accomplishment
Instructions of Boeing Alert Service Bulletin 737-53A1357, dated
August 9, 2016, terminates the inspection requirements of paragraph
(g) of this AD.

(i) Alternative Methods of Compliance (AMOCs)

    (1) The Manager, Los Angeles Aircraft Certification Office
(ACO), FAA, has the authority to approve AMOCs for this AD, if
requested using the procedures found in 14 CFR 39.19. In accordance
with 14 CFR 39.19, send your request to your principal inspector or
local Flight Standards District Office, as appropriate. If sending
information directly to the manager of the ACO, send it to the
attention of the person identified in paragraph (j)(1) of this AD.
Information may be emailed to<EMAIL_ADDRESS>    (2) Before using any approved AMOC, notify your appropriate
principal inspector, or lacking a principal inspector, the manager
of the local flight standards district office/certificate holding
district office.
    (3) An AMOC that provides an acceptable level of safety may be
used for any repair, modification, or alteration required by this AD
if it is approved by the Boeing Commercial Airplanes Organization
Designation Authorization (ODA) that has been authorized by the
Manager, Los Angeles ACO, to make those findings. To be approved,
the repair method, modification deviation, or alteration deviation
must meet the certification basis of the airplane, and the approval
must specifically refer to this AD.
    (4) For service information that contains steps that are labeled
as Required for Compliance (RC), the provisions of paragraphs
(i)(4)(i) and (i)(4)(ii) of this AD apply.
    (i) The steps labeled as RC, including substeps under an RC step
and any figures identified in an RC step, must be done to comply
with the AD. If a step or substep is labeled ``RC Exempt,'' then the
RC requirement is removed from that step or substep. An AMOC is
required for any deviations to RC steps, including substeps and
identified figures.
    (ii) Steps not labeled as RC may be deviated from using accepted
methods in accordance with the operator's maintenance or inspection
program without obtaining approval of an AMOC, provided the RC
steps, including substeps and identified figures, can still be done
as specified, and the airplane can be put back in an airworthy
condition.

(j) Related Information

    (1) For more information about this AD, contact Galib Abumeri,
Aerospace Engineer, Airframe Branch, ANM-120L, FAA, Los Angeles ACO,
3960 Paramount Boulevard, Lakewood, CA 90712-4137; phone: 562-627-
5324; fax:<PHONE_NUMBER>; email<EMAIL_ADDRESS>    (2) For service information identified in this AD, contact
Boeing Commercial Airplanes, Attention: Contractual & Data Services
(C&DS), 2600 Westminster Blvd., MC 110-SK57, Seal Beach, CA 90740-
5600; telephone<PHONE_NUMBER>; Internet https://www.myboeingfleet.com. You may view this referenced service
information at the FAA, Transport Airplane Directorate, 1601 Lind
Avenue SW., Renton, WA. For information on the availability of this
material at the FAA, call<PHONE_NUMBER>.

    Issued in Renton, Washington, on March 14, 2017.
Dionne Palermo,
Acting Manager, Transport Airplane Directorate, Aircraft Certification
Service.
[FR Doc. 2017-05519 Filed 3-22-17; 8:45 am]
 BILLING CODE 4910-13-P


[Federal Register Volume 86, Number 227 (Tuesday, November 30, 2021)]
[Notices]
[Pages 67956-67958]
[FR Doc No: 2021-26006]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2021-D-1146]

Real-World Data: Assessing Registries To Support Regulatory
Decision-Making for Drug and Biological Products; Draft Guidance for
Industry; Availability

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of availability.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA or Agency) is announcing
the availability of a draft guidance for industry entitled ``Real-World
Data: Assessing Registries to Support Regulatory Decision-Making for
Drug and Biological Products.'' FDA is issuing this guidance as part of
its Real-World Evidence (RWE) Program and to satisfy, in part, the
mandate under the Federal Food, Drug, and Cosmetic Act (FD&C Act) to
issue guidance about the use of RWE in regulatory decision-making. This
guidance provides sponsors and other stakeholders with considerations
when either proposing to design a registry or using an existing
registry to support regulatory decision-making about a drug's
effectiveness or safety.

DATES: Submit either electronic or written comments on the draft
guidance by February 28, 2022 to ensure that the Agency considers your
comment on this draft guidance before it begins work on the final
version of the guidance.

ADDRESSES: You may submit comments on any guidance at any time as
follows:

Electronic Submissions

    Submit electronic comments in the following way:
     Federal eRulemaking Portal: https://www.regulations.gov.
Follow the instructions for submitting comments. Comments submitted
electronically, including attachments, to https://www.regulations.gov
will be posted to the docket unchanged. Because your comment will be
made public, you are solely responsible for ensuring that your comment
does not include any confidential information that you or a third party
may not wish to be posted, such as medical information, your or anyone
else's Social Security number, or confidential business information,
such as a manufacturing process. Please note that if you include your
name, contact information, or other information that identifies you in
the body of your comments, that information will be posted on https://www.regulations.gov.
     If you want to submit a comment with confidential
information that you do not wish to be made available to the public,
submit the comment as a written/paper submission and in the manner
detailed (see ``Written/Paper Submissions'' and ``Instructions'').

Written/Paper Submissions

    Submit written/paper submissions as follows:
     Mail/Hand Delivery/Courier (for written/paper
submissions): Dockets Management Staff (HFA-305), Food and Drug
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
     For written/paper comments submitted to the Dockets
Management Staff, FDA will post your comment, as well as any
attachments, except for information submitted, marked and identified,
as confidential, if submitted as detailed in ``Instructions.''
    Instructions: All submissions received must include the Docket No.
FDA-2021-D-1146 for ``Real-World Data: Assessing Registries to Support
Regulatory Decision-Making for Drug and Biological Products.'' Received
comments will be placed in the docket and, except for those submitted
as ``Confidential Submissions,'' publicly viewable at https://www.regulations.gov or at the Dockets Management Staff between 9 a.m.
and 4 p.m., Monday through Friday,<PHONE_NUMBER>.

     Confidential Submissions--To submit a comment with
confidential information that you do not wish to be made publicly
available, submit your comments only as a written/paper submission. You
should submit two copies total. One copy will include the information
you claim to be confidential with a heading or cover note that states
``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' The Agency will
review this copy, including the claimed confidential information, in
its consideration of comments. The second copy, which will have the
claimed confidential information redacted/blacked out, will be
available for public viewing and posted on https://www.regulations.gov.
Submit both copies to the Dockets Management Staff. If you do not wish
your name and contact information to be made publicly available, you
can provide this information on the cover sheet and not in the body of
your comments and you must identify this information as
``confidential.'' Any information marked as ``confidential'' will not
be disclosed except in accordance with 21 CFR 10.20 and other
applicable disclosure law. For more information about FDA's posting of
comments to public dockets, see 80 FR 56469, September 18, 2015, or
access the information at: https://www.govinfo.gov/content/pkg/FR-2015-09-18/pdf/2015-23389.pdf.
    Docket: For access to the docket to read background documents or
the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in
the heading of this document, into the ``Search'' box and follow the
prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane,
Rm. 1061, Rockville, MD 20852,<PHONE_NUMBER>.
    You may submit comments on any guidance at any time (see 21 CFR
10.115(g)(5)).
    Submit written requests for single copies of the draft guidance to
the Division of Drug Information, Center for Drug Evaluation and
Research, Food and Drug Administration, 10001 New Hampshire Ave.,
Hillandale Building, 4th Floor, Silver Spring, MD 20993-0002; or to the
Office of Communication, Outreach and Development, Center for Biologics
Evaluation and Research, Food and Drug Administration, 10903 New
Hampshire Ave., Bldg. 71, Rm. 3128, Silver Spring, MD 20993-0002. Send
one self-addressed adhesive label to assist that office in processing
your requests. See the SUPPLEMENTARY INFORMATION section for electronic
access to the draft guidance document.

FOR FURTHER INFORMATION CONTACT: Dianne Paraoan, Center for Drug
Evaluation and Research, Food and Drug Administration, 10903 New
Hampshire Ave., Bldg. 51, Rm. 3326, Silver Spring, MD 20993-0002, 301-
796-3161, [email protected]; or Stephen Ripley, Center for
Biologics Evaluation and Research, Food and Drug Administration, 10903
New Hampshire Ave., Bldg. 71, Rm. 7301, Silver Spring, MD 20993-0002,
240-402-7911.

SUPPLEMENTARY INFORMATION:

I. Background

    FDA is announcing the availability of a draft guidance for industry
entitled ``Real-World Data: Assessing Registries to Support Regulatory
Decision-Making for Drug and Biological Products.'' FDA is issuing this
guidance as part of its RWE Program and to satisfy, in part, the
mandate under section 505F of the FD&C Act (21 U.S.C. 355g) to issue
guidance about the use of RWE in regulatory decision-making. Topics
covered in this guidance include:

 A registry's fitness-for-use for regulatory decision-making,
focusing on attributes of a registry that support the collection of
relevant and reliable data
 Considerations when linking a registry to another data source,
such as data from medical claims, electronic health records, digital
health technologies, or another registry
 Considerations for supporting FDA review of submissions,
including registry data

    Section 3022 of the 21st Century Cures Act (Cures Act) (Pub. L.
114-255) amended the FD&C Act to add section 505F, Utilizing Real World
Evidence. This section requires the establishment of a program to
evaluate the potential use of RWE to help support the approval of a new
indication for a drug approved under section 505(c) of the FD&C Act (21
U.S.C. 355(c)) and to help support or satisfy postapproval study
requirements. This section also requires that FDA utilize the program
to inform guidance for industry on the circumstances under which
sponsors of drugs may rely on RWE and the appropriate standards and
methodologies for collection and analysis of RWE submitted to evaluate
the potential use of RWE for those purposes. Further, under the
Prescription Drug User Fee Amendments of 2017 (PDUFA VI), FDA committed
to publishing draft guidance on how RWE can contribute to the
assessment of safety and effectiveness in regulatory submissions. FDA
is issuing this draft guidance as part of a series of guidance
documents to satisfy the Cures Act mandate and the PDUFA VI commitment.
    This draft guidance is being issued consistent with FDA's good
guidance practices regulation (21 CFR 10.115). The draft guidance, when
finalized, will represent the current thinking of FDA on ``Real-World-
Data: Assessing Registries to Support Regulatory Decision-Making for
Drug and Biological Products.'' It does not establish any rights for
any person and is not binding on FDA or the public. You can use an
alternative approach if it satisfies the requirements of the applicable
statutes and regulations.

II. Paperwork Reduction Act of 1995

    While this guidance contains no collection of information, it does
refer to previously approved FDA collections of information. Therefore,
clearance by the Office of Management and Budget (OMB) under the
Paperwork Reduction Act of 1995 (PRA) (44 U.S.C. 3501-3521) is not
required for this guidance. The previously approved collections of
information are subject to review by OMB under the PRA. The collections
of information in 21 CFR part 11 have been approved under OMB control
number 0910-0303. The collections of information in 21 CFR parts 50 and
56 have been approved under OMB control number 0910-0130. The
collections of information in 21 CFR 201.56 and 201.57 have been
approved under OMB control number 0910-0572. The collections of
information in 21 CFR parts 310 and 314 have been approved under OMB
control number 0910-0230. The collections of information in 21 CFR
parts 310, 314, 600, and 803 have been approved under OMB control
number 0910-0291. The collections of information in 21 CFR parts 310,
314, 600, and 803 have been approved under OMB control number 0910-
0645. The collections of information in 21 CFR part 312 have been
approved under OMB control number 0910-0014. The collections of
information in 21 CFR part 314 have been approved under OMB control
number 0910-0001. The collections of information in 21 CFR part 601
have been approved under OMB control number 0910-0338. The collections
of information in 21 CFR part 600 have been approved under OMB control
number 0910-0308. The collections of information in 21 CFR part 812
have been approved under OMB control number 0910-0078. The collections
of information in FDA's guidance for industry entitled ``Formal
Meetings with Sponsors and Applicants

for PDUFA Products'' have been approved under OMB control number 0910-
0429.

III. Electronic Access

    Persons with access to the internet may obtain the draft guidance
at https://www.fda.gov/drugs/guidance-compliance-regulatory-information/guidances-drugs, https://www.fda.gov/vaccines-blood-biologics/guidance-compliance-regulatory-information-biologics/biologics-guidances, https://www.fda.gov/regulatory-information/search-fda-guidance-documents, or https://www.regulations.gov.

    Dated: November 23, 2021.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2021-26006 Filed 11-29-21; 8:45 am]
BILLING CODE 4164-01-P


[Federal Register Volume 80, Number 32 (Wednesday, February 18, 2015)]
[Notices]
[Page 8677]
[FR Doc No: 2015-03368]

-----------------------------------------------------------------------

DEPARTMENT OF HOMELAND SECURITY

Federal Emergency Management Agency

[Docket ID: FEMA-2015-0008; OMB No. 1660-0030]

Agency Information Collection Activities: Proposed Collection;
Comment Request; Manufactured Housing Operations Forms

AGENCY: Federal Emergency Management Agency, DHS.

ACTION: Notice; correction.

-----------------------------------------------------------------------

    On February 9, 2015, the Federal Emergency Management Agency (FEMA)
published an agency information collection notice in the Federal
Register at 80 FR 7005. In the For Further Information Contact section,
FEMA inadvertently listed the email address for the Records Management
Division as<EMAIL_ADDRESS>It
should be<EMAIL_ADDRESS>
    Dated: February 11, 2015.
Charlene D. Myrthil,
Director, Records Management Division, Mission Support, Federal
Emergency Management Agency, Department of Homeland Security.
[FR Doc. 2015-03368 Filed 2-17-15; 8:45 am]
BILLING CODE 9111-23-P


[Federal Register Volume 86, Number 110 (Thursday, June 10, 2021)]
[Notices]
[Pages 30929-30930]
[FR Doc No: 2021-12200]

-----------------------------------------------------------------------

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Docket No. AD21-10-000]

Modernizing Electricity Market Design; Notice Inviting Post-
Technical Conference Comments

    On May 25, 2021, the Federal Energy Regulatory Commission
(Commission) convened a technical conference to discuss resource
adequacy, state policies and ISO-New England Inc.'s markets.
    All interested persons are invited to file post-technical
conference comments to address issues raised during the technical
conference and identified in the Supplemental Notice of Technical
Conference issued May 17, 2021. For reference, the questions included
in the Supplemental Notice are included below. Commenters need not
answer all of the questions but are encouraged to organize responses
using the numbering and order in the below questions. Commenters are
also invited to reference material previously filed in this docket but
are encouraged to avoid repetition or replication of previous material.
Comments are due 45 days from the date of this Notice.
    Comments may be filed electronically via the internet.\1\
Instructions are available on the Commission's website http://www.ferc.gov/docs-filing/efiling.asp. For assistance, please contact
FERC Online Support at<EMAIL_ADDRESS>or toll free at 1-
866-208-3676, or for TTY,<PHONE_NUMBER>.
---------------------------------------------------------------------------

    \1\ See 18 CFR 385.2001(a)(1)(iii) (2020).
---------------------------------------------------------------------------

    For more information about this Notice, please contact: David
Rosner (Technical Information), Office of Energy Policy and Innovation,
Federal Energy Regulatory Commission, 888 First Street NE, Washington,
DC 20426,<PHONE_NUMBER><EMAIL_ADDRESS>    Meghan O'Brien (Legal Information), Office of the General Counsel,
Federal Energy Regulatory Commission, 888 First Street NE, Washington,
exception occurred on : 2021-12200.htm
exception occurred on : 2021-12200.htm
DC 20426,<PHONE_NUMBER>, Meghan.O'[email protected].

    Dated: June 4, 2021.
Debbie-Anne A. Reese,
Deputy Secretary.

Post-Technical Conference Questions for Comment

1. Relationship Between State Policies and ISO New England Inc.'s
Markets

    a. In October 2020, the New England States Committee on Electricity
(NESCOE) released a vision statement that called for ISO-NE to provide
an appropriate level of state involvement in wholesale market design
and implementation.\2\ Please provide an update on the discussions in
the region since the vision statement was released.
---------------------------------------------------------------------------

    \2\ NESCOE, New England States' Vision for a Clean, Affordable,
and Reliable 21st Century Regional Electric Grid, http://nescoe.com/resource-center/vision-stmt-oct2020/.
---------------------------------------------------------------------------

    b. Please explain how states are currently involved in market
design and implementation processes. How are states' perspectives
considered in these processes? How is information shared with states
related to these processes? What is the appropriate role for New
England states with respect to ISO-NE capacity market reforms?
    c. New England Power Pool (NEPOOL), in coordination with NESCOE and
ISO-NE representatives, launched the ``New England's Future Grid
Initiative'' in two parallel processes to (1) define and assess the
future state of the region's power system; and (2) explore and evaluate
potential market frameworks that could be pursued to accommodate state
policies focused on decarbonization.\3\ What is the current status of
each of these stakeholder processes?
---------------------------------------------------------------------------

    \3\ ISO-NE, New England's Future Grid Initiative Key Project,
https://www.iso-ne.com/committees/key-projects/new-englands-future-grid-initiative-key-project/. See also Dr. Frank Felder, NEPOOL's
Pathways to the Future Grid Process Project Report n.1 (Jan. 2021),
https://nepool.com/wp-content/uploads/2021/01/NPC_20210107_Felder_Report_on_Pathways_rev1.pdf.
---------------------------------------------------------------------------

    d. Many New England states have established long-term policy goals
and/or statutory requirements to reduce greenhouse gas emissions and
increase clean energy generation. Consistent with these goals, several
states have instituted programs to promote the development of renewable
energy resources and to retain existing zero-emitting generation
resources. How do the current ISO-NE market rules affect implementation
of existing or proposed state policies? If states have differing policy
goals, how should these be accommodated in the ISO-NE capacity market?
How do one state's actions to shape the resource mix affect other
states? Should such effects be addressed, and if so, how?
    e. Is ISO-NE's existing capacity market design, including the
Competitive Auctions with Sponsored Policy Resources (CASPR) framework
effective in ensuring resource adequacy at just and reasonable rates?
Why or why not? Is it compatible with achieving New England states'
policies? Given the small quantity of capacity cleared through the
substitution auction, is CASPR achieving its goals? Is CASPR's current
design durable? Why, or why not?

2. Short-Term Options and Complementary Potential Market Changes To
Accommodate State Policies in ISO-NE

    a. Should ISO-NE's capacity market design, including the CASPR
framework, change to better accommodate state policies? If so, how?
    b. As the resource mix in ISO-NE continues to evolve, what new
challenges are presented? Are the needs of the evolving resource mix
better addressed in the capacity market or the energy and ancillary
services markets, or are changes needed in both? Please explain.
    c. At the March 23, 2021 technical conference,\4\ panelists
suggested that

both short-term and long-term reforms to aspects of ISO-NE's capacity,
energy, and ancillary services markets could be needed if CASPR and the
Offer Review Trigger Prices (ORTPs) are modified or eliminated.
---------------------------------------------------------------------------

    \4\ See Supplemental Notice of Technical Conference on Resource
Adequacy in the Evolving Electricity Sector, Docket No. AD21-10-000
(March 16, 2021), https://www.ferc.gov/sites/default/files/2021-03/AD21-10-000supp.pdf.
---------------------------------------------------------------------------

    i. What, if any, are the short-term and long-term challenges of
removing CASPR and the ORTPs from ISO-NE's capacity market? What market
design changes, if any, would be necessary to preserve the capacity
market's ability to ensure resource adequacy? If changes are necessary,
how quickly would ISO-NE need to implement short-term changes following
the removal of CASPR and ORTP?
    ii. What other specific modifications to ISO-NE's capacity market
rules may be necessary? For example, should capacity accreditation
rules for various resource types, the shape of the capacity market
demand curve, the net cost of new entry estimates, or mechanisms to
ensure fuel security, among others, be revised and if so why, and how?
Approximately how long would it take ISO-NE and stakeholders to develop
and implement each additional needed reform? Assuming any such
modifications are necessary, which should be prioritized in the short-
term, and which should be pursued in the long-term?
    iii. Some panelists expressed concerns that ORTPs are necessary to
prevent cost shifts between New England states. Please explain whether
and if so, how these cost shifts would occur if CASPR and the ORTPs
were eliminated. Is there a way to mitigate such an effect? Please
explain. Additionally, please discuss the extent to which certain
impacts are unavoidable in a regional market where participating
resources are located in multiple states.

3. Long-Term Options and Centralized Procurement of Clean Energy

    a. What benefits would a centralized clean procurement mechanism in
ISO-NE provide to the ISO-NE states and the ISO-NE markets? What would
be the goals of such approaches and what are important design
considerations in developing any potential market mechanism? What are
the downsides of pursuing such constructs? What concerns regarding
potential undue discrimination may arise from implementing such new
market constructs, if any?
    b. What are potential challenges to developing the new market
constructs discussed in this panel (e.g., would interstate compacts be
required)? How could those challenges be overcome? For example, New
England states have policies that support different types of resources
(e.g., offshore wind). Could a standard product be developed and
centrally procured in ISO-NE-administered markets to meet these diverse
state policy goals? Given the differences in state policies, is it
possible to define products that resources could provide (e.g., zero-
emission generation) and incorporate the procurement of those products
into Commission-jurisdictional markets?
    c. Stakeholder discussions to date have focused on the Forward
Clean Energy Market and Integrated Clean Capacity Market as potential
frameworks. What are the key design features of these proposals? What
are the advantages and disadvantages of these approaches?
    d. Given that many state policy goals target electricity generation
(e.g., Renewable Portfolio Standards that target a percentage of
electric loads), would it be more effective to develop such a construct
within the energy and ancillary services markets?
[FR Doc. 2021-12200 Filed 6-9-21; 8:45 am]
BILLING CODE 6717-01-P


[Federal Register Volume 78, Number 112 (Tuesday, June 11, 2013)]
[Notices]
[Pages 35016-35017]
[FR Doc No: 2013-13767]

-----------------------------------------------------------------------

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

Combined Notice of Filings 1

    Take notice that the Commission received the following electric
rate filings:
    Docket Numbers: ER12-2159-003.
    Applicants: Canadian Hills Wind, LLC.
    Description: Notice of Non-Material Change in Status of Canadian
Hills Wind, LLC.
    Filed Date: 6/3/13.
    Accession Number: 20130603-5167.
    Comments Due: 5 p.m. ET 6/24/13.

    Docket Numbers: ER13-535-003.
    Applicants: PJM Interconnection, L.L.C.
    Description: Compliance Filing to 5/2/2013 MOPR Order in ER13-535-
000, 001 to be effective 2/5/2013.
    Filed Date: 6/3/13.
    Accession Number: 20130603-5162.
    Comments Due: 5 p.m. ET 6/24/13.

    Docket Numbers: ER13-692-004.
    Applicants: Midcontinent Independent System Operator, Inc.
    Description: 06-03-2013 OASIS Compliance Filing to be effective 6/
4/2013.
    Filed Date: 6/4/13.
    Accession Number: 20130604-5000.
    Comments Due: 5 p.m. ET 6/25/13.

    Docket Numbers: ER13-983-000.
    Applicants: Arizona Public Service Company.
    Description: Refund Report for MPP Westwing Substation
Interconnection Construction Agreement to be effective N/A.
    Filed Date: 6/3/13.
    Accession Number: 20130603-5147.
    Comments Due: 5 p.m. ET 6/24/13.

    Docket Numbers: ER13-1346-000.
    Applicants: Mesa Wind Power Corporation.
    Description: Supplement to April 26, 2013 Mesa Wind Power
Corporation tariff filing.
    Filed Date: 6/3/13.
    Accession Number: 20130603-5120.
    Comments Due: 5 p.m. ET 6/24/13.

    Docket Numbers: ER13-1630-000.
    Applicants: California Independent System Operator Corporation, AES
Huntington Beach, L.L.C.
    Description: Amendments to RMR Agreement to be effective 6/26/2013.
    Filed Date: 6/3/13.
    Accession Number: 20130603-5161.
    Comments Due: 5 p.m. ET 6/24/13.

    Docket Numbers: ER13-1631-000.
    Applicants: Midcontinent Independent System Operator, Inc.
    Description: Request for Waiver of certain tariff provisions of
Midcontinent Independent System Operator, Inc.
    Filed Date: 6/4/13.
    Accession Number: 20130604-5039.
    Comments Due: 5 p.m. ET 6/25/13.

    Docket Numbers: ER13-1632-000.
    Applicants: Chandler Wind Partners, LLC.
    Description: Chandler Wind Partners, LLC submits First Revised MBR
to be effective 6/5/2013.

    Filed Date: 6/4/13.
    Accession Number: 20130604-5065.
    Comments Due: 5 p.m. ET 6/25/13.

    Docket Numbers: ER13-1633-000.
    Applicants: Westar Energy, Inc.
    Description: Westar Energy, Inc. submits Nemaha-Marshall Electric
Cooperative Association, Inc. to be effective 6/1/2013.
    Filed Date: 6/4/13.
    Accession Number: 20130604-5090.
    Comments Due: 5 p.m. ET 6/25/13.
    The filings are accessible in the Commission's eLibrary system by
clicking on the links or querying the docket number.
    Any person desiring to intervene or protest in any of the above
proceedings must file in accordance with Rules 211 and 214 of the
Commission's Regulations (18 CFR 385.211 and 385.214) on or before 5:00
p.m. Eastern time on the specified comment date. Protests may be
considered, but intervention is necessary to become a party to the
proceeding.
    eFiling is encouraged. More detailed information relating to filing
requirements, interventions, protests, service, and qualifying
facilities filings can be found at: http://www.ferc.gov/docs-filing/efiling/filing-req.pdf. For other information, call<PHONE_NUMBER>
(toll free). For TTY, call<PHONE_NUMBER>.

    Dated: June 4, 2013.
Nathaniel J. Davis, Sr.,
Deputy Secretary.
[FR Doc. 2013-13767 Filed 6-10-13; 8:45 am]
BILLING CODE 6717-01-P


[Federal Register Volume 87, Number 196 (Wednesday, October 12, 2022)]
[Rules and Regulations]
[Pages 61450-61452]
[FR Doc No: 2022-22014]

-----------------------------------------------------------------------

DEPARTMENT OF TRANSPORTATION

Federal Aviation Administration

14 CFR Part 39

[Docket No. FAA-2022-0802; Project Identifier AD-2021-01094-R;
Amendment 39-22210; AD 2022-21-11]
RIN 2120-AA64

Airworthiness Directives; Bell Textron Inc. Helicopters and
Various Restricted Category Helicopters

AGENCY: Federal Aviation Administration (FAA), DOT.

ACTION: Final rule.

-----------------------------------------------------------------------

SUMMARY: The FAA is adopting a new airworthiness directive (AD) for
certain Bell Textron Inc. Model 204B, 205A, and 205A-1 helicopters and
various restricted category helicopters. This AD was prompted by a
report of cracked main rotor blades (MRBs). This AD requires repetitive
inspections of each MRB and removing any cracked MRB from service. The
FAA is issuing this AD to address the unsafe condition on these
products.

DATES: This AD is effective November 16, 2022.

ADDRESSES: For service information identified in this final rule,
contact Bell Textron, Inc., P.O. Box 482, Fort Worth, TX, 76101, United
States; phone:<PHONE_NUMBER>; website: bellflight.com/support/. You
may view this service information at the FAA, Office of the Regional
Counsel, Southwest Region, 10101 Hillwood Pkwy., Room 6N-321, Fort
Worth, TX 76177. For information on the availability of this material
at the FAA, call<PHONE_NUMBER>.

Examining the AD Docket

    You may examine the AD docket at regulations.gov by searching for
and locating Docket No. FAA-2022-0802; or in person at Docket
Operations between 9 a.m. and 5 p.m., Monday through Friday, except
Federal holidays. The AD docket contains this final rule, any comments
received, and other information. The address for Docket Operations is
U.S. Department of Transportation, Docket Operations, M-30, West
Building Ground Floor, Room W12-140, 1200 New Jersey Avenue SE,
Washington, DC 20590.

FOR FURTHER INFORMATION CONTACT: Hye Yoon Jang, Aerospace Engineer,
Delegation Oversight Section, DSCO Branch, Compliance & Airworthiness
Division, FAA, 10101 Hillwood Pkwy., Fort Worth, TX 76177; telephone
(817) 222-5190; email [email protected].

SUPPLEMENTARY INFORMATION:

Background

    The FAA issued a notice of proposed rulemaking (NPRM) to amend 14
CFR part 39 by adding an AD that would apply to certain serial-numbered
Bell Textron Inc. Model 204B, 205A, and 205A-1 helicopters, and all
restricted category Model HH-1K, SW205A-1, TH-1F, TH-1L, UH-1A, UH-1B,
UH-1E, UH-1F, UH-1H, UH-1L, and UH-1P helicopters, with MRB part number
(P/N) 204-011-250-001, -005, -009, -113, or -117 installed.
    The NPRM published in the Federal Register on June 29, 2022 (87 FR
38686). The NPRM was prompted by reports of chordwise cracks in MRB P/N
204-011-250-113. The cracks originated from the extreme trailing edge
between blade station 190 and 210; this area is currently not inspected
during routine maintenance. In the NPRM, the FAA proposed to require
cleaning certain areas of the upper and lower skin surfaces of each MRB
with a cheesecloth. If the cheesecloth is snagged or frayed while
cleaning an MRB, removing paint from the area that caused the snagging
and then either visually or eddy current inspecting the area for a
crack would be required. The NPRM also proposed to require wiping each
MRB with isopropyl alcohol and immediately after the blade dries,
inspecting the area for a dark line, which is an indication that excess
alcohol is bleeding out of a crack or edge void. If there is a dark
line, removing paint from the area where there is a dark line and
inspecting for a crack in the skin would be required. Finally, the NPRM
proposed to require removing any cracked MRB from service. The FAA is
issuing this AD to address the unsafe condition on these products.

Discussion of Final Airworthiness Directive

Comments

    The FAA received comments from one commenter, Salmon River
Helicopters (SRH). SRH commented about allowing a pilot to accomplish
the daily (before first flight of each day) inspection. The following
presents the comment received on the NPRM and the FAA's response.

Comment Regarding the Before the First Flight of Each Day Inspection

    SRH asked whether a pilot may accomplish the daily (before the
first flight of each day) inspection. SRH stated that it has never had
an issue with blade cracking between blade stations 190 and 210, and is
unaware of reported accidents due to blade cracking within those
stations. SRH further stated that many operators, like SRH, do not
staff a mechanic every day of flight and it would be a significant
disadvantage to do so.
    The FAA partially agrees. The FAA agrees to allow the owner/
operator (pilot) to accomplish the actions required by paragraph
(g)(1)(i) of this AD because it only involves cleaning with a
cheesecloth and visually checking for unsmooth areas and surfaces that
snag the cheesecloth or cause it to fray. These actions could be
performed equally well by a pilot or a mechanic, and is an exception to
the FAA's standard maintenance regulations. The FAA disagrees with a
pilot accomplishing the remaining required actions because those
actions must be accomplished by a mechanic that meets the requirements
of 14 CFR part 65 subpart D.

Conclusion

    The FAA reviewed the relevant data, considered any comments
received, and determined that air safety requires adopting this AD as
proposed. Accordingly, the FAA is issuing this AD to address the unsafe
condition on these products. Except for minor editorial changes, and
any other changes described previously, this AD is adopted as proposed
in the NPRM. None of the changes will increase the economic burden on
any operator.

Related Service Information

    The FAA reviewed the following Bell Alert Service Bulletins (ASBs),
each Revision A and dated October 12, 2018, and for helicopters with
MRB P/N 204-011-250-001, -005, -009, -113, or -117:
     Bell ASB 204-96-49 for Model 204B helicopters, serial
numbers (S/N) 2001 through 2070 and 2196 through 2199 and
     Bell ASB 205-96-67 for Model 205A and 205A-1 helicopters,
S/N 30001 through 30332.
    The FAA also reviewed Bell ASB UH-1H-18-20, dated October 23, 2018,
for all Model UH-IH helicopters with MRB P/N 204-011-250-113 installed.
    These service bulletins specify procedures for daily wipe down
inspections and 25-hour inspections of the MRBs for cracks.

Costs of Compliance

    The FAA estimates that this AD affects 682 helicopters of U.S.
registry. Labor rates are estimated at $85 per work-hour. Based on
these numbers, the FAA estimates the following costs to comply with
this AD.
    Each MRB inspection takes about .5 work-hour and parts cost $50 for
an estimated cost of $93 per helicopter and $63,426 for the U.S. fleet,
per inspection cycle.
    Replacing an MRB, if required, takes about 10 work-hours and parts
cost about $157,815 per blade for an estimated cost of $158,665 per MRB
replacement.

Authority for This Rulemaking

    Title 49 of the United States Code specifies the FAA's authority to
issue rules on aviation safety. Subtitle I, section 106, describes the
authority of the FAA Administrator. Subtitle VII: Aviation Programs,
describes in more detail the scope of the Agency's authority.
    The FAA is issuing this rulemaking under the authority described in
Subtitle VII, Part A, Subpart III, Section 44701: General requirements.
Under that section, Congress charges the FAA with promoting safe flight
of civil aircraft in air commerce by prescribing regulations for
practices, methods, and procedures the Administrator finds necessary
for safety in air commerce. This regulation is within the scope of that
authority because it addresses an unsafe condition that is likely to
exist or develop on products identified in this rulemaking action.

Regulatory Findings

    This AD will not have federalism implications under Executive Order
13132. This AD will not have a substantial direct effect on the States,
on the relationship between the national government and the States, or
on the distribution of power and responsibilities among the various
levels of government.
    For the reasons discussed above, I certify that this AD:
    (1) Is not a ``significant regulatory action'' under Executive
Order 12866,
    (2) Will not affect intrastate aviation in Alaska, and
    (3) Will not have a significant economic impact, positive or
negative, on a substantial number of small entities under the criteria
of the Regulatory Flexibility Act.

List of Subjects in 14 CFR Part 39

    Air transportation, Aircraft, Aviation safety, Incorporation by
reference, Safety.

The Amendment

    Accordingly, under the authority delegated to me by the
Administrator, the FAA amends 14 CFR part 39 as follows:

PART 39--AIRWORTHINESS DIRECTIVES

0
1. The authority citation for part 39 continues to read as follows:

    Authority:  49 U.S.C. 106(g), 40113, 44701.

Sec.  39.13  [Amended]

0
2. The FAA amends Sec.  39.13 by adding the following new airworthiness
directive:

2022-21-11 Bell Textron Inc., and Various Restricted Category
Helicopters: Amendment 39-22210; Docket No. FAA-2022-0802; Project
Identifier AD-2021-01094-R.

(a) Effective Date

    This airworthiness directive (AD) is effective November 16,
2022.

(b) Affected ADs

    None.

(c) Applicability

    This AD applies to the following helicopters with main rotor
blade (MRB) part number 204-011-250-001, -005, -009, -113, or -117
installed:
    (1) Bell Textron Inc. Model 204B helicopters, serial numbers (S/
N) 2001 through 2070 and 2196 through 2199, inclusive, certificated
in any category;
    (2) Bell Textron Inc. Model 205A, and 205A-1 helicopters, S/N
30001 through 30332, inclusive, certificated in any category; and
    (3) Various restricted category helicopters:
    (i) Model HH-1K helicopters; current type certificate holders
include, but are not limited to, Rotorcraft Development Corporation;
    (ii) Southwest Florida Aviation International, Inc., Model
SW205A-1 helicopters;
    (iii) Model TH-1F helicopters; current type certificate holders
include, but are not limited to, Robinson Air Crane Inc.; Rotorcraft
Development Corporation; and Tamarack Helicopters, Inc.;
    (iv) Model TH-1L helicopters; current type certificate holders
include, but are not limited to, Bell Textron Inc.; Overseas
Aircraft Support, Inc.; and Rotorcraft Development Corporation;
    (v) Model UH-1A helicopters; current type certificate holders
include, but are not limited to, Richards Heavylift Helo, Inc.;
    (vi) Model UH-1B helicopters; current type certificate holders
include, but are not limited to, International Helicopters, Inc.;
Overseas Aircraft Support, Inc.; Red Tail Flying Services, LLC;
Richards Heavylift Helo, Inc.; Rotorcraft Development Corporation;
Southwest Florida Aviation International, Inc.; and WSH, LLC (type
certificate previously held by San Joaquin Helicopters);
    Note 1 to paragraph (c)(3)(vi): Helicopters with an SW204 or
SW204HP designation are Southwest Florida Aviation International,
Inc., Model UH-1B helicopters.
    (vii) Model UH-1E helicopters; current type certificate holders
include, but are not limited to, Bell Textron Inc.; Overseas
Aircraft Support, Inc.; Rotorcraft Development Corporation; Smith
Helicopters; and West Coast Fabrications;
    (viii) Model UH-1F helicopters; current type certificate holders
include, but are not limited to, AST, Inc.; California Department of
Forestry; Robinson Air Crane, Inc.; Rotorcraft Development
Corporation; and Tamarack Helicopters, Inc.;
    (ix) Model UH-1H helicopters; current type certificate holders
include, but are not limited to, Arrow Falcon Exporters, Inc.;
Global Helicopter Technology, Inc.; Hagglund Helicopters, LLC;
JJASPP Engineering Services LLC; Northwest Rotorcraft, LLC; Overseas
Aircraft Support, Inc.; Richards Heavylift Helo, Inc.; Rotorcraft
Development Corporation; Southwest Florida Aviation International,
Inc.; and Tamarack Helicopters, Inc.;
    Note 2 to paragraph (c)(3)(ix): Helicopters with an SW205
designation are Southwest Florida Aviation International, Inc.,
Model UH-1H helicopters.
    (x) Model UH-1L helicopters; current type certificate holders
include, but are not limited to, Bell Textron Inc.; Overseas
Aircraft Support, Inc.; and Rotorcraft Development Corporation; and
    (xi) Model UH-1P helicopters; current type certificate holders
include, but are not limited to, Robinson Air Crane, Inc.; and
Rotorcraft Development Corporation.

(d) Subject

    Joint Aircraft System Component (JASC) Code: 6210, Main rotor
blades.

(e) Unsafe Condition

    This AD was prompted by a report of cracks on the MRBs outside
of the current inspection area. The FAA is issuing this AD to
prevent a failure of an MRB. The unsafe condition, if not addressed,
could result in loss of an MRB and subsequent loss of control of the
helicopter.

(f) Compliance

    Comply with this AD within the compliance times specified,
unless already done.

(g) Required Actions

    (1) As of the effective date of this AD, before the first flight
of each day:
    (i) Using cheesecloth, clean the upper and lower skin surfaces
of each MRB in the area between blade stations 100 through 215,
noting any unsmooth areas and paying attention to the trailing edge
and any MRB surface which snag the cheesecloth or cause it to fray,
as this may by an indication of a crack or paint chip that could
lead to corrosion.
    (ii) The actions required by paragraph (g)(1)(i) of this AD may
be performed by the owner/operator (pilot) holding at least a
private pilot certificate, and must be entered into the aircraft
records showing compliance with this AD in accordance with 14 CFR

43.9(a) and 14 CFR 91.417(a)(2)(v). The record must be maintained as
required by 14 CFR 91.417, 121.380, or 135.439.
    (iii) If there is any unsmooth area or the cheesecloth used to
clean the MRB is snagged or frayed, remove paint from the area that
is unsmooth or caused the snagging or fraying (affected area) by
hand sanding in a spanwise direction with an abrasive cloth or
sandpaper 220 or smoother grit and either:
    (A) Visually inspect the affected area for any crack using a 10X
or higher power magnifying glass with a flashlight applied at an
oblique angle and perpendicular to the crack orientation; or
    (B) Eddy current inspect the affected area for any crack using a
surface probe.
    (iv) If there is any crack, before further flight, remove the
MRB from service.
    (2) As of the effective date of this AD, at intervals not to
exceed 25 hours time-in-service, prepare the upper and lower skin
surfaces of each MRB for inspection by wiping the last 4 inches of
the trailing edge between blade station 100 and 215 with an
isopropyl alcohol-soaked cloth and then drying the area with a clean
cloth. Immediately after drying the area, using a flashlight at an
oblique angle, inspect the surface for a dark line, as this is an
indication that excess isopropyl alcohol is bleeding out of a crack
or edge void. If there is a dark line, remove paint from the area
where there is a dark line by hand sanding in a spanwise direction
with an abrasive cloth or sandpaper 220 or smoother grit and inspect
for a crack in the skin. If there is any crack, before further
flight, remove the MRB from service.

(h) Alternative Methods of Compliance (AMOCs)

    (1) The Manager, DSCO Branch, FAA, has the authority to approve
AMOCs for this AD, if requested using the procedures found in 14 CFR
39.19. In accordance with 14 CFR 39.19, send your request to your
principal inspector or local Flight Standards District Office, as
appropriate. If sending information directly to the manager of the
certification office, send it to the attention of the person
identified in paragraph (i) of this AD. Information may be emailed
to: [email protected].
    (2) Before using any approved AMOC, notify your appropriate
principal inspector, or lacking a principal inspector, the manager
of the local flight standards district office/certificate holding
district office.

(i) Related Information

    For more information about this AD, contact Hye Yoon Jang,
Aerospace Engineer, Delegation Oversight Section, DSCO Branch,
Compliance & Airworthiness Division, FAA, 10101 Hillwood Pkwy., Fort
Worth, TX 76177; telephone<PHONE_NUMBER>; email
[email protected].

(j) Material Incorporated by Reference

    None.

    Issued on October 4, 2022.
Christina Underwood,
Acting Director, Compliance & Airworthiness Division, Aircraft
Certification Service.
[FR Doc. 2022-22014 Filed 10-11-22; 8:45 am]
BILLING CODE 4910-13-P


[Federal Register Volume 81, Number 153 (Tuesday, August 9, 2016)]
[Notices]
[Pages 52695-52696]
[FR Doc No: 2016-18814]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2016-N-2147]

General and Plastic Surgery Devices Panel of the Medical Devices
Advisory Committee; Notice of Meeting, Establishment of a Public
Docket, Request for Comments

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice, establishment of a public docket, request for comments.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) announces a forthcoming
public advisory committee meeting of the General and Plastic Surgery
Devices Panel of the Medical Devices Advisory Committee. The general
function of the committee is to provide advice and recommendations to
the Agency on FDA's regulatory issues. The meeting will be open to the
public. FDA is establishing a docket for public comment on this
document.

DATES: The meeting will be held on September 20 and 21, 2016, from 8
a.m. to 6 p.m.

ADDRESSES: Hilton Washington, DC North/Gaithersburg, Grand Ballroom,
620 Perry Pkwy., Gaithersburg, MD 20877. The hotel's telephone number
is<PHONE_NUMBER>. Answers to commonly asked questions including
information regarding special accommodations due to a disability,
visitor parking, and transportation may be accessed at: http://www.fda.gov/AdvisoryCommittees/AboutAdvisoryCommittees/ucm408555.htm.
    You may submit comments as follows:

Electronic Submissions

    Submit electronic comments in the following way:
     Federal eRulemaking Portal: http://www.regulations.gov.
Follow the instructions for submitting comments. Comments submitted
electronically, including attachments, to http://www.regulations.gov
will be posted to the docket unchanged. Because your comment will be
made public, you are solely responsible for ensuring that your comment
does not include any confidential information that you or a third party
may not wish to be posted, such as medical information, your or anyone
else's Social Security number, or confidential business information,
such as a manufacturing process. Please note that if you include your
name, contact information, or other information that identifies you in
the body of your comments, that information will be posted on http://www.regulations.gov.
     If you want to submit a comment with confidential
information that you do not wish to be made available to the public,
submit the comment as a written/paper submission and in the manner
detailed (see ``Written/Paper Submissions'' and ``Instructions'').

Written/Paper Submissions

    Submit written/paper submissions as follows:
     Mail/Hand delivery/Courier (for written/paper
submissions): Division of Dockets Management (HFA-305), Food and Drug
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
     For written/paper comments submitted to the Division of
Dockets Management, FDA will post your comment, as well as any
attachments, except for information submitted, marked and identified,
as confidential, if submitted as detailed in ``Instructions.''
    Instructions: All submissions received must include the Docket No.
FDA-2016-N-2147 for ``General and Plastic Surgery Devices Panel of the
Medical Devices Advisory Committee; Notice of Meeting; Establishment of
a Public Docket; Request for Comments.'' Received comments will be
placed in the docket and, except for those submitted as ``Confidential
Submissions,'' publicly viewable at http://www.regulations.gov or at
the Division of Dockets Management between 9 a.m. and 4 p.m., Monday
through Friday.
     Confidential Submissions--To submit a comment with
confidential information that you do not wish to be made publicly
available, submit your comments only as a written/paper submission. You
should submit two copies total. One copy will include the information
you claim to be confidential with a heading or cover note that states
``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' The Agency will
review this copy, including the claimed confidential information, in
its consideration of comments. The second copy, which will have the
claimed confidential information redacted/blacked out, will be
available for public viewing and posted on http://www.regulations.gov.
Submit both copies to the Division of Dockets Management. If you do not
wish your name and contact information to be made publicly available,
you can provide this information on the cover sheet and not in the body
of your

comments and you must identify this information as ``confidential.''
Any information marked as ``confidential'' will not be disclosed except
in accordance with 21 CFR 10.20 and other applicable disclosure law.
For more information about FDA's posting of comments to public dockets,
see 80 FR 56469, September 18, 2015, or access the information at:
http://www.fda.gov/regulatoryinformation/dockets/default.htm.
    Docket: For access to the docket to read background documents or
the electronic and written/paper comments received, go to http://www.regulations.gov and insert the docket number, found in brackets in
the heading of this document, into the ``Search'' box and follow the
prompts and/or go to the Division of Dockets Management, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.

FOR FURTHER INFORMATION CONTACT: Evella Washington, Center for Devices
and Radiological Health, Food and Drug Administration, 10903 New
Hampshire Ave., Bldg. 66, Rm. 1535, Silver Spring, MD 20993-0002, 301-
796-6683<EMAIL_ADDRESS>or FDA Advisory Committee
Information Line, 1-800-741-8138<PHONE_NUMBER> in the Washington, DC
area).
    A notice in the Federal Register about last minute modifications
that impact a previously announced advisory committee meeting cannot
always be published quickly enough to provide timely notice. Therefore,
you should always check the Agency's Web site at http://www.fda.gov/AdvisoryCommittees/default.htm and scroll down to the appropriate
advisory committee meeting link, or call the advisory committee
information line to learn about possible modifications before coming to
the meeting.

SUPPLEMENTARY INFORMATION:
    Agenda: On September 20 and 21, 2016, the Committee will discuss
and make recommendations regarding the classification of certain wound
care products containing antimicrobials and other drugs as part of the
routine process for device classification. These products are regulated
under product code FRO, ``Dressing, Wound, Drug,'' and are considered
``pre-amendments'' because they were in commercial distribution prior
to May 28, 1976, when the Medical Devices Amendments were enacted, and
have not yet been classified under section 513 of the Federal Food,
Drug, and Cosmetic Act.
    As a part of the classification process, FDA is seeking committee
input on the indications for use, risks to health, and safety and
effectiveness of these wound care products, and how they should be
classified. They may be classified in class I (general controls), class
II (special and general controls), or class III (premarket approval
(PMA), requiring demonstration of safety and effectiveness for each
product).
    FDA believes some of these products may meet the definition of
class II whereas others may meet the definition of class III in light
of their intended use, composition, the extent of evidence of clinical
benefit, and the risks they pose. For the subset of the these products
that contain antibiotics, FDA appreciates the importance of
appropriately addressing the risk of antimicrobial resistance (AMR) in
light of the increasingly significant national public health concern
posed by AMR. FDA is also aware of differences in the claims made for
some products even though they may be regulated in the same manner.
    FDA intends to make background material available to the public on
its Web site at least 2 business days before the meeting. If FDA is
unable to post the background material on its Web site prior to the
meeting, the background material will be made publicly available at the
location of the meeting, and the background material will be posted on
FDA's Web site after the meeting. Background material will be available
at http://www.fda.gov/AdvisoryCommittees/Calendar/default.htm. Scroll
down to the appropriate advisory committee meeting link.
    Procedure: Interested persons may present data, information, or
views, orally or in writing, on issues pending before the committee.
Written submissions may be made to the contact person on or before
September 6, 2016. Oral presentations from the public will be scheduled
between approximately 1 p.m. and 2 p.m. on September 20 and between
approximately 9 a.m. and 10:30 a.m. on September 21, 2016. Those
individuals interested in making formal oral presentations should
notify the contact person and submit a brief statement of the general
nature of the evidence or arguments they wish to present, the names and
addresses of proposed participants, and an indication of the
approximate time requested to make their presentation on or before
August 26, 2016. Time allotted for each presentation may be limited. If
the number of registrants requesting to speak is greater than can be
reasonably accommodated during the scheduled open public hearing
session, FDA may conduct a lottery to determine the speakers for the
scheduled open public hearing session. The contact person will notify
interested persons regarding their request to speak by August 29, 2016.
    Persons attending FDA's advisory committee meetings are advised
that the Agency is not responsible for providing access to electrical
outlets.
    FDA is establishing a docket for public comment on this document.
The docket number is FDA-2016-N-2147. The docket will close on October
20, 2016. Comments received on or before September 1, 2016, will be
provided to the committee. Comments received after that date will be
taken into consideration by the Agency.
    For press inquiries, please contact the Office of Media Affairs at
<EMAIL_ADDRESS>or<PHONE_NUMBER>.
    FDA welcomes the attendance of the public at its advisory committee
meetings and will make every effort to accommodate persons with
disabilities. If you require accommodations due to a disability, please
contact AnnMarie Williams at<EMAIL_ADDRESS>or 301-796-
5966 at least 7 days in advance of the meeting.
    FDA is committed to the orderly conduct of its advisory committee
meetings. Please visit our Web site at http://www.fda.gov/AdvisoryCommittees/AboutAdvisoryCommittees/ucm111462.htm for procedures
on public conduct during advisory committee meetings.
    Notice of this meeting is given under the Federal Advisory
Committee Act (5 U.S.C. app. 2).

    Dated: August 3, 2016.
Janice M. Soreth,
Acting Associate Commissioner, Special Medical Programs.
[FR Doc. 2016-18814 Filed 8-8-16; 8:45 am]
 BILLING CODE 4164-01-P


[Federal Register Volume 77, Number 182 (Wednesday, September 19, 2012)]
[Notices]
[Pages 58134-58136]
[FR Doc No: 2012-22966]

-----------------------------------------------------------------------

ENVIRONMENTAL PROTECTION AGENCY

[EPA-HQ-OPP-2009-1017; FRL-9361-1]

Notice of Receipt of Requests To Voluntarily Cancel Certain
Pesticide Registrations

AGENCY: Environmental Protection Agency (EPA).

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: In accordance with the Federal Insecticide, Fungicide, and
Rodenticide Act (FIFRA), EPA is issuing a notice of receipt of requests
by registrants to voluntarily cancel certain pesticide registrations.
EPA intends to grant these requests at the close of the comment period
for this announcement unless the Agency receives substantive comments
within the comment period that would merit its further review of the
requests, or unless the registrants withdraw its requests. If these
requests are granted, any sale, distribution, or use of products listed
in this notice will be permitted after the registration has been
cancelled only if such sale, distribution, or use is consistent with
the terms as described in the final order.

DATES: Comments must be received on or before October 19, 2012.

ADDRESSES: Submit your comments, identified by docket identification
(ID) number EPA-HQ-OPP-2009-1017, by one of the following methods:
     Federal eRulemaking Portal: http://www.regulations.gov.
Follow the online instructions for submitting comments. Do not submit
electronically any information you consider to be Confidential Business
Information (CBI) or other information whose disclosure is restricted
by statute.
     Mail: OPP Docket, Environmental Protection Agency Docket
Center (EPA/DC), (28221T), 1200 Pennsylvania Ave. NW., Washington, DC
20460-0001.
    Submit written withdrawal request by mail to: Pesticide Re-
evaluation Division (7508P), Office of Pesticide Programs,
Environmental Protection Agency, 1200 Pennsylvania Ave. NW.,
Washington, DC 20460-0001. ATTN: Katie Weyrauch.
     Hand Delivery: To make special arrangements for hand
delivery or delivery of boxed information, please follow the
instructions at http://www.epa.gov/dockets/contacts.htm.
    Additional instructions on commenting or visiting the docket, along
with more information about dockets generally, is available at http://www.epa.gov/dockets.

FOR FURTHER INFORMATION CONTACT: Katie Weyrauch, Pesticide Re-
evaluation Division (7508P), Office of Pesticide Programs,
Environmental Protection Agency, 1200 Pennsylvania Ave. NW.,
Washington, DC 20460-0001; telephone number:<PHONE_NUMBER>; email
address<EMAIL_ADDRESS>
SUPPLEMENTARY INFORMATION:

I. General Information

A. Does this action apply to me?

    This action is directed to the public in general, and may be of
interest to a wide range of stakeholders including environmental, human
health, and agricultural advocates; the chemical industry; pesticide
users; and members of the public interested in the sale, distribution,
or use of pesticides.

B. What should I consider as I prepare my comments for EPA?

    1. Submitting CBI. Do not submit this information to EPA through
regulations.gov or email. Clearly mark the part or all of the
information that you claim to be CBI. For CBI information in a disk or
CD-ROM that you mail to EPA, mark the outside of the disk or CD-ROM as
CBI and then identify electronically within the disk or CD-ROM the
specific information that is claimed as CBI. In addition to one
complete version of the comment that includes information claimed as
CBI, a copy of the comment that does not contain the information
claimed as CBI must be submitted for inclusion in the

public docket. Information so marked will not be disclosed except in
accordance with procedures set forth in 40 CFR part 2.
    2. Tips for preparing your comments. When submitting comments,
remember to:
    i. Identify the document by docket ID number and other identifying
information (subject heading, Federal Register date and page number).
    ii. Follow directions. The Agency may ask you to respond to
specific questions or organize comments by referencing a Code of
Federal Regulations (CFR) part or section number.
    iii. Explain why you agree or disagree; suggest alternatives and
substitute language for your requested changes.
    iv. Describe any assumptions and provide any technical information
and/or data that you used.
    v. If you estimate potential costs or burdens, explain how you
arrived at your estimate in sufficient detail to allow for it to be
reproduced.
    vi. Provide specific examples to illustrate your concerns and
suggest alternatives.
    vii. Explain your views as clearly as possible, avoiding the use of
profanity or personal threats.
    viii. Make sure to submit your comments by the comment period
deadline identified.

II. What action is the agency taking?

    This notice announces receipt by the Agency of requests from
registrants to cancel 18 pesticide products registered under FIFRA
section 3 or 24(c). These registrations are listed in sequence by
registration number (or company number and 24(c) number) in Table 1 of
this unit.
    Unless the Agency determines that there are substantive comments
that warrant further review of the requests or the registrants withdraw
their requests, EPA intends to issue an order in the Federal Register
canceling all of the affected registrations.

      Table 1--Registrations With Pending Requests for Cancellation
------------------------------------------------------------------------
      Registration No.            Product name          Chemical name
------------------------------------------------------------------------
002724-00622................  Speer Py-Perm         Piperonyl butoxide;
                               Aqueous Insect        Pyrethrins;
                               Killer 5.    Permethrin.
002724-00633................  Speer Py-Perm         Piperonyl butoxide;
                               Aqueous Insect        Pyrethrins;
                               Killer 9.    Permethrin.
007405-00073................  Chemi-cap Flying &    Pyrethrins,
                               Crawling              Piperonyl butoxide,
                               Insecticide II.       Permethin.
011678-00072................  MCW Technical         Diflubenzuron.
                               Diflubenzuron.
015300-00011................  Chemical Treatment    Poly(oxy-1,2-
                               CT-202.               ethanediyl(dimethyl
                                                     imino)-1,2-
                                                     ethanediyl(dimethyl
                                                     imino)-1,2-
                                                     ethanediyl
                                                     dichloride).
015300-00022................  Chemical Treatment    Poly(oxy-1,2-
                               CL-2158.              ethanediyl(dimethyl
                                                     imino)-1,2-
                                                     ethanediyl(dimethyl
                                                     imino)-1,2-
                                                     ethanediyl
                                                     dichloride).
015300-00023................  Chemical Treatment    Poly(oxy-1,2-
                               CL-2159.              ethanediyl(dimethyl
                                                     imino)-1,2-
                                                     ethanediyl(dimethyl
                                                     imino)-1,2-
                                                     ethanediyl
                                                     dichloride).
047000-00169................  R & M Flea & Tick     Piperonyl butoxide,
                               Shampoo 3.   Pyrethrins.
052867-00001................  Microbiotrol 99W....  Poly(oxy-1,2-
                                                     ethanediyl(dimethyl
                                                     imino)-1,2-
                                                     ethanediyl(dimethyl
                                                     imino)-1,2-
                                                     ethanediyl
                                                     dichloride).
066222-00059................  Propiconazole         Propiconazole.
                               Technical.
066330-00371................  Tribenuron-methyl     Tribenuron-methyl.
                               Technical.
070908-00003................  NAC 20..............  Boric acid.
073049-00441................  Dinotefuran 0.5%      Dinotefuran.
                               Cockroach Gel Bait
                               Professional.
073049-00442................  Dinotefuran 0.5%      Dinotefuran.
                               Roach Bait Stations.
073049-00443................  Dinotefuran 0.2%      Dinotefuran.
                               Roach Bait Station.
073049-00446................  Shuriken Cockroach    Dinotefuran.
                               Gel.
081343-00001................  Mykrostat A-100.....  10,10'-
                                                     Oxybisphenoxarsine.
CA010023....................  Goal 2XL Herbicide..  Oxyfluorfen.
------------------------------------------------------------------------

    Table 2 of this unit includes the names and addresses of record for
all registrants of the products in Table 1 of this unit, in sequence by
EPA company number. This number corresponds to the first part of the
EPA registration numbers of the products listed in this unit.

         Table 2--Registrants Requesting Voluntary Cancellation
------------------------------------------------------------------------
          EPA Company No.                 Company name and address
------------------------------------------------------------------------
2724..............................  Wellmark International, 1501 E.
                                     Woodfield Rd., Suite 200 West,
                                     Schaumburg, IL 60173.
7405..............................  CPC Aeroscience, Inc., P.O. Box
                                     667770, Pompano Beach, FL 33066-
                                     7770.
11678.............................  Makhteshim Chemical Works Ltd, 3120
                                     Highwoods Blvd., Suite 100,
                                     Raleigh, NC 27604.
15300.............................  Chemtreat, Inc, 5640 Cox Rd., Glen
                                     Allen, VA 23060.
47000.............................  Chem-Tech, LTD, 4515 Fleur Dr.
                                     303, Des Moines, IA 50321.
52867.............................  Chemical Equipment Labs, P.O. Box A,
                                     Havertown, PA 19083.
66222.............................  Makhteshim Agan of North America,
                                     Inc., 3120 Highwoods Blvd., Suite
                                     100, Raleigh, NC 27604.
66330.............................  Arysta Life Science North America,
                                     LLC, 15401 Weston Parkway, Suite
                                     150, Cary, NC 27513.
70908.............................  Grow More, Inc, Agent: RegWest
                                     Company, LLC , 8203 West 20th St.,
                                     Suite A, Greeley, CO 80634-4696.
73049.............................  Valent BioSciences Corporation,
                                     Environmental Science Division, 870
                                     Technology Way, Libertyville, IL
                                     60048-6316.
81343.............................  MyTech, Inc, 751 Queen Ann St.,
                                     Burlington, NC 27217.

CA010023..........................  Dow AgroSciences LLC, 9330
                                     Zionsville Rd., 308/2E,
                                     Indianapolis, IN 46268-1054.
------------------------------------------------------------------------

III. What is the agency's authority for taking this action?

    Section 6(f)(1) of FIFRA provides that a registrant of a pesticide
product may at any time request that any of its pesticide registrations
be cancelled. FIFRA further provides that, before acting on the
request, EPA must publish a notice of receipt of any such request in
the Federal Register.
    Section 6(f)(1)(B) of FIFRA requires that before acting on a
request for voluntary cancellation, EPA must provide a 30-day public
comment period on the request for voluntary cancellation or use
termination. In addition, FIFRA section 6(f)(1)(C) requires that EPA
provide a 180-day comment period on a request for voluntary
cancellation or termination of any minor agricultural use before
granting the request, unless:
    1. The registrants request a waiver of the comment period, or
    2. The EPA Administrator determines that continued use of the
pesticide would pose an unreasonable adverse effect on the environment.
    The registrants in Table 2 of Unit II, have requested that EPA
waive the 180-day comment period. Accordingly, EPA will provide a 30-
day comment period on the proposed requests.

IV. Procedures for Withdrawal of Request

    Registrants who choose to withdraw a request for cancellation
should submit such withdrawal in writing to the person listed under FOR
FURTHER INFORMATION CONTACT. If the products have been subject to a
previous cancellation action, the effective date of cancellation and
all other provisions of any earlier cancellation action are
controlling.

V. Provisions for Disposition of Existing Stocks

    Existing stocks are those stocks of registered pesticide products
that are currently in the United States and that were packaged,
labeled, and released for shipment prior to the effective date of the
cancellation action. Because the Agency has identified no significant
potential risk concerns associated with these pesticide products, upon
cancellation of the products identified in Table 1 of Unit II., EPA
anticipates allowing registrants to sell and distribute existing stocks
of these products for 1 year after publication of the Cancellation
Order in the Federal Register. Thereafter, registrants will be
prohibited from selling or distributing the pesticides identified in
Table 1 of Unit II., except for export consistent with FIFRA section 17
or for proper disposal. Persons other than registrants will generally
be allowed to sell, distribute, or use existing stocks until such
stocks are exhausted, provided that such sale, distribution, or use is
consistent with the terms of the previously approved labeling on, or
that accompanied, the cancelled products.

List of Subjects

    Environmental protection, Pesticides and pests.

    Dated: September 11, 2012.
 Richard P. Keigwin, Jr.,
Director, Pesticide Re-evaluation Division, Office of Pesticide
Programs.
[FR Doc. 2012-22966 Filed 9-18-12; 8:45 am]
BILLING CODE 6560-50-P


[Federal Register Volume 84, Number 224 (Wednesday, November 20, 2019)]
[Notices]
[Pages 64125-64127]
[FR Doc No: 2019-25105]

-----------------------------------------------------------------------

SECURITIES AND EXCHANGE COMMISSION

[Release No. 34-87536; File No. SR-LCH SA-2019-010]

Self-Regulatory Organizations; LCH SA; Notice of Filing and
Immediate Effectiveness of Proposed Rule Change Relating to Amendments
to LCH SA's Fee Grid for Non Cash Collateral

November 14, 2019.
    Pursuant to Section 19(b)(1) of the Securities Exchange Act of 1934
(``Act'') \1\ and Rule 19b-4 thereunder \2\ notice is hereby given that
on October 31, 2019, Banque Centrale de Compensation, which conducts
business under the name LCH SA (``LCH SA''), filed with the Securities
and Exchange Commission (``Commission'') the proposed rule change
described in Items I, II and III below, which Items have been prepared
primarily by LCH SA. LCH SA filed the proposed rule change pursuant to
Section 19(b)(3)(A) of the Act,\3\ and Rule 19b-4(f)(2) \4\ thereunder,
so that the proposed rule change was effective upon filing with the
Commission. The Commission is publishing this notice to solicit
comments on the proposed rule change from interested persons.
---------------------------------------------------------------------------

    \1\ 15 U.S.C. 78s(b)(1).
    \2\ 17 CFR 240.19b-4.
    \3\ 15 U.S.C. 78s(b)(3)(A).
    \4\ 17 CFR 240.19b-4(f)(2).
---------------------------------------------------------------------------

I. Clearing Agency's Statement of the Terms of Substance of the
Proposed Rule Change

    Banque Centrale de Compensation, which conducts business under the
name LCH SA (``LCH SA''), is proposing to review and modify its current
fee grid applied for Non Cash Collateral (NCC) across all clearing
services including CDSClear.
    The text of the proposed rule change has been annexed as Exhibit
5.\5\
---------------------------------------------------------------------------

    \5\ All capitalized terms not defined herein have the same
definition as the Rule Book, Supplement or Procedures, as
applicable.
---------------------------------------------------------------------------

II. Clearing Agency's Statement of the Purpose of, and Statutory Basis
for, the Proposed Rule Change

    In its filing with the Commission, LCH SA included statements
concerning the purpose of and basis for the proposed rule change and
discussed any comments it received on the proposed rule change. The
text of these statements may be examined at the places specified in
Item IV below. LCH SA has prepared summaries, set forth in sections A,
B, and C below, of the most significant aspects of these statements.

A. Clearing Agency's Statement of the Purpose of, and Statutory Basis
for, the Proposed Rule Change.

1. Purpose
    LCH SA is currently applying the below fee grid for CDSClear
members:

----------------------------------------------------------------------------------------------------------------
                                                                FFT                           Pledge
                 Collateral type                 ---------------------------------------------------------------
                                                    House (bps)    Client (bps)     House (bps)    Client (bps)
----------------------------------------------------------------------------------------------------------------
Government Bonds................................              10              10              10              10
Supranational Bonds.............................             N/A             N/A             N/A             N/A
Agency Bonds....................................              10              10              10              10
----------------------------------------------------------------------------------------------------------------

    From November 1st, 2019, LCH SA is proposing to extend the scope of
instruments eligible to margin collateral to EUR denominated bonds
issued by a number of supranational and agency institutions. LCH SA is
also proposing to extend the possibility to use the pledge solution in
Euroclear Bank for the other LCH SA clearing services (namely RepoClear
and EquityClear the ``Non US Business'' \6\). In this context, LCH SA
is moving to apply more differentiation in its collateral fee grid and
thus CDSClear has decided to harmonize its existing non-cash collateral
fee grid for house collateral with that of the other LCH SA clearing
services.
---------------------------------------------------------------------------

    \6\ See the definition under Order Granting Application for
Registration as a Clearing Agency and Request for Exemptive Relief,
Order, Securities Exchange Act Release No. 34-79707; File No. 600-36
(Dec. 29, 2016), 82 FR 1398 (Jan. 5, 2017) (available at https://www.federalregister.gov/documents/2017/01/05/2016-31940/self-regulatory-organizations-lch-sa-order-granting-application-for-registration-as-a-clearing).
---------------------------------------------------------------------------

    The objective of the proposed fee change is to differentiate the
pricing by type of non-cash collateral accepted by LCH SA and deposit
facility. These changes will be applicable across all LCH SA clearing
services with the exception of CDSClear's client collateral fees that
will differ from house fees and remain at their current level for all
non-cash securities.
    No amendments to the LCH SA CDS Clearing Rules are required to
effect these changes.
    As specified in the fee grid attached under Exhibit 5, the proposed
house collateral fee change is for CDSClear to:
    (i) Increase the fee rate from 10 bps to 11 bps for full title
transfer of Government issued bonds; \7\
---------------------------------------------------------------------------

    \7\ To become effective on April 1st, 2020
---------------------------------------------------------------------------

    (ii) introduce a fee rate of 13 bps for full title transfer of
Supranational issued bonds;
    (iii) increase the fee rate from 10bps to 13bps for full title
transfer of Agency issued bonds;
    (iv) increase the fee rate from 10bps to 15bps for all pledged
securities.
    For CDSClear clients, a fee rate of 10 bps will be introduced for
full title transfer of Supranational bonds. No other changes will be
made to CDSClear's client collateral fees.
2. Statutory Basis.
    Section 17A(b)(3)(D) of the Act requires that the rules of a
clearing agency provide for the equitable allocation of reasonable
dues, fees, and other charges.\8\
---------------------------------------------------------------------------

    \8\ 15 U.S.C. 78q-1(b)(3)(D).
---------------------------------------------------------------------------

    LCH SA believes that its clearing fee change proposal is consistent
with the requirements of Section 17A of the Act \9\ and the regulations
thereunder applicable to it, and in particular provides for the
equitable allocation of reasonable fees, dues, and other charges among
clearing members and market participants by ensuring that clearing
members and clients pay reasonable fees and dues for the services
provided by LCH SA, within the meaning of Section 17A(b)(3)(D) of the
Act.
---------------------------------------------------------------------------

    \9\ 15 U.S.C. 78q-1.
---------------------------------------------------------------------------

    The extension of the non-cash eligible securities along with the
extension of the pledge facility is an improvement of service that
offers all LCH SA's members and clients more choice and therefore more
opportunities to better tailor their collateral management to their
needs but it also does bear consequences on LCH SA's balance sheet as a
whole and therefore on its liquidity ratio management.
    Currently the pledge facility is only available to CDSClear members
and clients with a very limited use. However, as a result of the
broadening of the pledge facility to Non US-Business, the expected
overall impact on LCH SA's liquidity ratio now needs to be carefully
monitored and managed. Further, in order to offer this enhanced
collateral management service, LCH SA has also invested in the
development of a number of additional systems and controls leading to
the review and changes of the applicable fee grid.
    Additionally, today, CDSClear members mainly post cash collateral
and we do not foresee that the fee changes will alter current market
practice amongst CDSClear's members and clients.
    As an illustration, from January 2018 to September 2019, the
percentage of collateral posted in securities was less than 20% on
average for house activity, supporting the assessment that these fee
changes will not have any material impact on CDSClear's revenues.
    For all the reasons stated above, LCH SA believes that the proposed
fee rates are reasonable and have been set up at an appropriate level
given the costs, expenses and revenues generated to LCH SA in providing
these improved collateral management services.

B. Clearing Agency's Statement on Burden on Competition.

    Section 17A(b)(3)(I) of the Act requires that the rules of a
clearing agency not impose any burden on competition not necessary or
appropriate in furtherance of the purposes of the Act.\10\
---------------------------------------------------------------------------

    \10\ 15 U.S.C. 78q-1(b)(3)(I).
---------------------------------------------------------------------------

    LCH SA does not believe that the proposed rule change would impose
any burden on competition that are not necessary or appropriate in
furtherance of the purposes of the Act.
    LCH SA is offering the possibility for CDSClear members and clients
to post a greater scope of instruments as eligible margin collateral.
Additionally, the proposed fee change will apply equally to all
CDSClear clearing members. Finally, the fee rate changes will not
adversely affect the ability of such members or other market
participants generally to engage in cleared transactions or to access
LCH SA's clearing services.

    Further, as explained above, LCH SA believes that the fee rates
have been set up at an appropriate level given the costs and expenses
to LCH SA in offering the relevant clearing services.

C. Clearing Agency's Statement on Comments on the Proposed Rule Change
Received From Members, Participants or Others

    Written comments relating to the proposed rule change have not been
solicited or received. LCH SA will notify the Commission of any written
comments received by LCH SA.

III. Date of Effectiveness of the Proposed Rule Change and Timing for
Commission Action

    The foregoing rule change has become effective pursuant to Section
19(b)(3)(A) of the Act and paragraph (f) of Rule 19b-4 thereunder. At
any time within 60 days of the filing of the proposed rule change, the
Commission summarily may temporarily suspend such rule change if it
appears to the Commission that such action is necessary or appropriate
in the public interest, for the protection of investors, or otherwise
in furtherance of the purposes of the Act.

IV. Solicitation of Comments

    Interested persons are invited to submit written data, views, and
arguments concerning the foregoing, including whether the proposed rule
change is consistent with the Act. Comments may be submitted by any of
the following methods:

Electronic Comments

     Use the Commission's internet comment form (http://www.sec.gov/rules/sro.shtml); or
     Send an email to<EMAIL_ADDRESS>Please include
File Number SR-LCH SA-2019-010 on the subject line.

Paper Comments

     Send paper comments in triplicate to Secretary, Securities
and Exchange Commission, 100 F Street NE, Washington, DC 20549-1090.

All submissions should refer to File Number SR-LCH SA-2019-010. This
file number should be included on the subject line if email is used. To
help the Commission process and review your comments more efficiently,
please use only one method. The Commission will post all comments on
the Commission's internet website (http://www.sec.gov/rules/sro.shtml).
Copies of the submission, all subsequent amendments, all written
statements with respect to the proposed rule change that are filed with
the Commission, and all written communications relating to the proposed
rule change between the Commission and any person, other than those
that may be withheld from the public in accordance with the provisions
of 5 U.S.C. 552, will be available for website viewing and printing in
the Commission's Public Reference Room, 100 F Street NE, Washington, DC
20549 on official business days between the hours of 10:00 a.m. and
3:00 p.m. Copies of the filing also will be available for inspection
and copying at the principal office of LCH SA and on LCH SA's website
at: https://www.lch.com/resources/rules-and-regulations/proposed-rule-changes-0. All comments received will be posted without change. Persons
submitting comments are cautioned that we do not redact or edit
personal identifying information from comment submissions. You should
submit only information that you wish to make available publicly. All
submissions should refer to File Number SR-LCH SA-2019-010 and should
be submitted on or before December 11, 2019.
---------------------------------------------------------------------------

    \11\ 17 CFR 200.30-3(a)(12).

    For the Commission, by the Division of Trading and Markets,
pursuant to delegated authority.\11\
Jill M. Peterson,
Assistant Secretary.
[FR Doc. 2019-25105 Filed 11-19-19; 8:45 am]
 BILLING CODE 8011-01-P